The United States Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for United States-based Verrica Pharmaceuticals Inc's (Nasdaq: VRCA), VP-102 (cantharidin 0.7% Topical Solution), a proprietary topical therapy intended for the treatment of contagious viral skin disease molluscum contagiosum (molluscum), it was reported yesterday.
The Prescription Drug User Fee Act (PUDFA) goal date assigned by the US FDA for this NDA is 13 July 2020.
The NDA is based on positive results from two identical Phase three randomised, double-blind, multicentre clinical trials (CAMP-1 and CAMP-2) that assessed the safety and efficacy of VP-102 compared to placebo in patients two years of age and older diagnosed with molluscum. In both trials, a clinically and statistically significant number of patients treated with VP-102 met the primary endpoint of complete clearance of all treatable molluscum lesions.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval